HepQuant Announces Approval of Second Investigational Device Exemption Application

HepQuant SHUNT™ Liver Diagnostic Kit for use in a clinical study in subjects with NASH F3

DENVER, CO (March 17, 2017) -- HepQuant, LLC, a Greenwood Village, Colorado-based company with a unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease, today announced that its first application for an Investigational Device Exemption ("IDE") for its HepQuant SHUNT™ Liver Diagnostic Kit has been approved by the Food and Drug Administration ("FDA") for use in a clinical study in subjects with Non-Alcoholic Steatohepatitis ("NASH") and a fibrosis score of F3.

Founder and Chief Executive Officer of HepQuant, LLC, Dr. Gregory T. Everson noted that the milestone "further represents HepQuant's study of the performance of the HepQuant SHUNT tests in subjects with NASH. NASH is a very serious liver disease and its prevalence has increased significantly since the 1990s. Unfortunately, NASH can progress to cirrhosis and is associated with liver cancer."

About HepQuant

HepQuant products are investigational combination drug / diagnostic devices and have not yet been evaluated or approved by the US Food and Drug Administration (FDA) for commercial sale. They are currently available for investigational use via the FDA IDE application process. For additional information, please visit our website at www.hepquant.com.

MEDIA CONTACT
Tom Kennedy, Corporate Communications
Ph: (303) 548-3056 | E: tom.kennedy@hepquant.com